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Due to a production error, Table 1 was inadvertently left out of the article as it was originally published. The table is printed below
and the online article has been corrected. We apologize for any confusion that may have occurred.Table 1. TET2 Mutations in B and T Cell Neoplasms
B cell ceoplasms All patients Mutated TET2
LPL 2 0 (0%)
PCN 22 0 (0%)
CLL /SLL 75 0 (0%)
TCRBL 3 0 (0%)
DLBCL 87 5 (5.7%)
MCL 22 0 (0%)
MZL 17 0 (0%)
FL 68 1 (1.5%)
Unspecified B-lymphoma 5 0 (0%)
Total 301 6 (2.0%)
T cell neoplasms All patients Mutated TET2
TLBL 5 1 (20%)
Leukemic or disseminated
(TPLL, TGLL, ATLL)
45 0 (0%)
Extranodal (ETCL, hepatosplenic) 4 0 (0%)
Extranodal cutaneous (Sezary, MF.) 42 2 (4.8%)
AITL 30 10 (33.3%)
ALCL 8 0 (0%)
PCTL, NOS 30 6 (20%)
Unspecified T-lymphoma 13 2 (15.4%)
Total 177 21 (11.9%)
LPL, lymphoplasmacytic lymphoma (including Waldenstro¨m macroglob-
ulinemia); PCN, plasma cell neoplasms (including plasma cell myeloma
and plasma cell leukemia); CLL, chronic lymphocytic leukemia; SLL,
small lymphocytic lymphoma; TCRBL, T cell-rich B cell lymphoma;
DLBCL, diffuse large B cell lymphoma; MCL, mantle cell lymphoma;
MZL,marginal zone lymphoma; FL, follicular lymphomal; TLBL: precursor
T-lymphoblastic lymphoma; TPLL, T cell prolymphocytic leukemia; TGLL,
T cell large granular lymphocytic leukemia; ATLL, adult T cell lymphoma/
leukemia (HTLV1+); ECTL, enteropathy-associated T cell lymphoma; MF,
mycosis fungoides; AITL, angioimmunoblastic T cell lymphoma; ALCL,
anaplastic large cell lymphoma; PCTL-NOS, peripheral T cell lymphoma
not otherwise specified.
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